Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.

PharmacoEconomics - open·2026
Same author

The management of NSAID-ERD patients in the current treatment landscape: aspirin desensitization, biologics, both, or neither?

The journal of allergy and clinical immunology. In practice·2026
Same author

Characteristics and clinical outcomes of patients with severe asthma receiving tezepelumab after marketing approval in Spain (T-ROSS II study): an observational study protocol.

BMJ open·2026
Same author

Rescue Inhaler Overuse in Severe Asthma: A Real-World Study of Short-Acting β<sub>2</sub>-Agonist and Short-Acting Muscarinic Antagonist Use.

Biomedicines·2026
Same author

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same author

Real-World Effectiveness of Tezepelumab Across T2 and Non-T2 Severe Asthma Phenotypes: A Multicenter Spanish Cohort Study.

Archivos de bronconeumologia·2026

Related Experiment Video

Updated: May 1, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Future biologic therapies in asthma.

Santiago Quirce1, Irina Bobolea1, Javier Domínguez-Ortega1

  • 1Servicio de Alergología, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, España.

Archivos De Bronconeumologia
|April 2, 2014
PubMed
Summary
This summary is machine-generated.

New biological therapies, including monoclonal antibodies targeting specific pathways like anti-IgE, IL-5, and IL-13, offer promising treatments for uncontrolled severe asthma. Personalized treatment based on patient phenoendotypes is crucial for effective asthma management.

Keywords:
Agentes biológicosAnticuerpos monoclonalesAsmaAsthmaBiological agentsMonoclonal antibodiesTherapyTratamiento

More Related Videos

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

629
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Related Experiment Videos

Last Updated: May 1, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
05:45

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis

Published on: January 16, 2026

629
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Many asthma patients remain uncontrolled despite standard treatments, necessitating novel therapeutic strategies.
  • Severe asthma, particularly uncontrolled cases, requires targeted and effective treatment options.
  • Biological therapies, especially monoclonal antibodies, are emerging as promising alternatives.

Purpose of the Study:

  • To review current and developing biological therapies for asthma.
  • To highlight the importance of phenoendotype-driven treatment selection.
  • To discuss the role of targeted cytokine blockade in severe asthma.

Main Methods:

  • Review of current literature on asthma biologics.
  • Analysis of targeted pathways including IgE, IL-5, IL-13, and IL-4.
  • Discussion of phenoendotyping for personalized medicine.

Main Results:

  • Anti-IgE therapy (omalizumab) is effective for severe allergic asthma.
  • Biologics targeting IL-5 (mepolizumab) and IL-13 (lebrikizumab) show clinical potential.
  • Combination blockade (e.g., IL-4 and IL-13 with dulipumab) may enhance efficacy.

Conclusions:

  • Biological therapies offer targeted treatment for severe asthma.
  • Personalized medicine through phenoendotyping is key for optimal asthma management.
  • Future asthma treatment will likely involve tailored biological interventions based on individual patient profiles.